Liquid Biopsy Market Insights: Size, Share, Growth Analysis & Forecast (2024-2029) 

The market report provided a comprehensive analysis segmented by Product & Service (Assay Kits, Instruments, Services); by Application (Early Cancer Screening, Therapy Selection, Treatment Monitoring, Recurrence Monitoring); by Circulating Biomarker (Circulating Tumor Cells, Cell-free DNA, Circulating Cell-Free RNA, Exosomes and Extracellular Vesicles, Others); by End User (Reference Laboratories, Hospital and Physician Laboratories, Academic & Research Centers, Others); by Geography (North America, South America, Asia Pacific, Europe, The Middle East, Africa).

Outlook 

• e liquid biopsy market is estimated to be at USD 6,223.33 Mn in 2024 and is anticipated to reach USD 11,740.11 Mn in 2029. 

• The liquid biopsy market is registering a CAGR of 13.54% during the forecast period of 2024-2029. 

• The global liquid biopsy market rapidly expands as a transformative tool in cancer diagnosis and monitoring. Liquid biopsy offers a non-invasive alternative to traditional tissue biopsies, enabling early cancer detection and monitoring of treatment responses through the analysis of circulating tumor cells (CTCs), cell-free DNA (cfDNA), and other biomarkers in blood samples. 

Request a free sample. 

Ecosystem 

• The global liquid biopsy industry participants constantly develop strategies to preserve a competitive advantage. 

• These companies drive innovation through continuous research and development, strategic collaborations, and the introduction of new products aimed at improving cancer diagnosis and patient outcomes. 

• Several important entities in the liquid biopsy market include Natera, Inc.; Qiagen N.V.; Myriad Genetics, Inc.; Illumina, Inc.; Roche Group; and others. 

Ask for customization. 

Findings 

Attributes	Values
Historical Period	2018-2022
Base Year	2023
Forecast Period	2024-2029
Market Size (2024)	USD 6,223.33 Mn
Market Size (2029)	USD 11,740.11 Mn
Growth Rate	13.54% CAGR from 2024 to 2029
Key Segments	Product & Service (Assay Kits, Instruments, Services); Application (Early Cancer Screening, Therapy Selection, Treatment Monitoring, Recurrence Monitoring); Circulating Biomarker (Circulating Tumor Cells, Cell-free DNA, Circulating Cell-Free RNA, Extracellular Vesicles, Circulating Tumor DNA, Others); End User (Reference Laboratories, Hospital and Physician Laboratories, Academic & Research Centers, Others); Geography (North America, South America, Asia Pacific, Europe, The Middle East, Africa)
Key Vendors	Natera, Inc.; Qiagen N.V.; Myriad Genetics, Inc.; Illumina, Inc.; Roche Group
Key Countries	The US; Canada; Mexico; Brazil; Argentina; Colombia; Chile; China; India; Japan; South Korea; The UK; Germany; Italy; France; Spain; Turkey; UAE; Saudi Arabia; Egypt; South Africa
Largest Market	North America

Get a free quote. 

Trends  

• Integration of AI and Big Data Analytics: The integration of artificial intelligence (AI) and big data analytics in liquid biopsy is becoming a prominent trend. AI-driven platforms are being developed to enhance the accuracy and speed of liquid biopsy tests, enabling complex genomic data analysis to identify patterns and predict outcomes. 

• Focus on Early Detection and Screening: The emphasis on early cancer detection drives the development of liquid biopsy tests specifically designed for cancer screening in asymptomatic individuals. Early detection significantly improves treatment outcomes, and liquid biopsy offers a less invasive option for widespread screening. 

• Emergence of Multi-Cancer Detection Tests: Multi-cancer detection tests are gaining traction, which can screen for multiple types of cancer from a single blood sample. These tests offer a comprehensive approach to cancer screening, making them an attractive option for patients and healthcare providers. In 2023, a new multi-cancer liquid biopsy test was launched in Europe, capable of detecting over 50 different types of cancer, marking a significant advancement in cancer diagnostics. 

Speak to analyst. 

Catalysts 

• Advancements in Genomic Technologies: Technological advancements in genomic sequencing and molecular diagnostics are propelling the growth of the liquid biopsy market. Next-generation sequencing (NGS) and digital PCR technologies have significantly improved the sensitivity and accuracy of liquid biopsies. In 2023, Illumina launched a new high-throughput sequencing platform designed explicitly for liquid biopsy applications, enhancing the ability to detect low-frequency mutations in blood samples. 

• Growing Adoption of Personalized Medicine: The shift towards personalized medicine drives the demand for liquid biopsy, as it allows for real-time monitoring of treatment responses and the detection of resistance mutations. This approach enables oncologists to tailor therapies based on a patient’s tumor’s genetic profile. 

• Non-invasive Nature and Patient Preference: A liquid biopsy’s non-invasive nature is a major advantage over traditional tissue biopsies, which can be painful and risky. Patients prefer liquid biopsy as it requires only a simple blood draw, making it easier to perform repeat testing to monitor disease progression and treatment efficacy. 

Inquire before buying. 

Restraints 

• Technical and Analytical Limitations: Despite advancements, liquid biopsy still faces technical challenges, such as the low concentration of circulating tumor DNA (ctDNA) in blood, which can lead to false negatives or inconclusive results. This issue arises because ctDNA often makes up only a tiny fraction of the total cell-free DNA in the bloodstream, making it difficult to detect at low levels. 

• High Cost of Liquid Biopsy Tests: The high cost of liquid biopsy tests is a significant barrier, limiting their accessibility, especially in low- and middle-income countries. These tests often require advanced technology, such as next-generation sequencing or high-resolution imaging, and specialized expertise, contributing to their high expense. Additionally, the need for sophisticated laboratory infrastructure and ongoing maintenance further increases the overall cost, making it challenging for many healthcare systems to adopt these technologies. 

• Regulatory and Reimbursement Challenges: Obtaining regulatory approval and securing reimbursement for liquid biopsy tests remain challenging, particularly due to varying regional standards. In 2023, the European Medicines Agency (EMA) implemented stricter regulations for diagnostic tests, including liquid biopsies, complicating market entry for new products and slowing down their adoption across Europe. 

Personalize this research. 

Hotspot 

Explore purchase options. 

Table of Contents 

1.       Introduction         1.1.    Research Methodology         1.2.    Scope of the Study  2.       Market Overview / Executive Summary         2.1.    Global Liquid Biopsy Market (2018 – 2022)         2.2.    Global Liquid Biopsy Market (2023 – 2029)  3.       Market Segmentation         3.1.    Global Liquid Biopsy Market by Product & Service                3.1.1.    Assay Kits                3.1.2.    Instruments                3.1.3.    Services         3.2.    Global Liquid Biopsy Market by Application                3.2.1.    Early Cancer Screening                3.2.2.    Therapy Selection                3.2.3.    Treatment Monitoring                3.2.4.    Recurrence Monitoring         3.3.    Global Liquid Biopsy Market by Circulating Biomarker                3.3.1.    Circulating Tumor Cells                3.3.2.    Cell-free DNA                3.3.3.    Circulating Cell-Free RNA                3.3.4.    Extracellular Vesicles                3.3.5.    Circulating Tumor DNA                3.3.6.    Others         3.4.    Global Liquid Biopsy Market by End User                3.4.1.    Reference Laboratories                3.4.2.    Hospital and Physician Laboratories                3.4.3.    Academic & Research Centers                3.4.4.    Others  4.       Regional Segmentation         4.1.    North America                4.1.1.    The US                4.1.2.    Canada                4.1.3.    Mexico         4.2.    South America                4.2.1.    Brazil                4.2.2.    Argentina                4.2.3.    Colombia                4.2.4.    Chile                4.2.5.    Rest of South America         4.3.    Asia Pacific                4.3.1.    China                4.3.2.    India                4.3.3.    Japan                4.3.4.    South Korea                4.3.5.    Rest of Asia Pacific         4.4.    Europe                4.4.1.    The UK                 4.4.2.    Germany                4.4.3.    Italy                4.4.4.    France                4.4.5.    Spain                4.4.6.    Rest of Europe         4.5.    The Middle East                4.5.1.    Turkey                4.5.2.    UAE                4.5.3.    Saudi Arabia                4.5.4.    Rest of the Middle East         4.6.    Africa                4.6.1.    Egypt                4.6.2.    South Africa                4.6.3.    Rest of Africa  5.       Value Chain Analysis of the Global Liquid Biopsy Market  6.       Porter Five Forces Analysis         6.1.    Threats of New Entrants         6.2.    Threats of Substitutes         6.3.    Bargaining Power of Buyers         6.4.    Bargaining Power of Suppliers         6.5.    Competition in the Industry  7.       Trends, Drivers and Challenges Analysis         7.1.    Market Trends         7.1.1.    Market Trend 1         7.1.2.    Market Trend 2         7.1.3.    Market Trend 3         7.2.    Market Drivers         7.2.1.    Market Driver 1         7.2.2.    Market Driver 2         7.2.3.    Market Driver 3         7.3.    Market Challenges         7.3.1.    Market Challenge 1         7.3.2.    Market Challenge 2         7.3.3.    Market Challenge 3  8.       Opportunities Analysis         8.1.    Market Opportunity 1         8.2.    Market Opportunity 2         8.3.    Market Opportunity 3  9.       Competitive Landscape         9.1.    Natera, Inc.         9.2.    Qiagen N.V.         9.3.    Myriad Genetics, Inc.         9.4.    Illumina, Inc.         9.5.    Roche Group         9.6.    Company 6         9.7.    Company 7         9.8.    Company 8         9.9.    Company 9         9.10.  Company 10

Know the research methodology. 

Liquid Biopsy Market – FAQs 

1.  What is the current size of the liquid biopsy market? 

Ans. In 2024, the liquid biopsy market size is USD 6,223.33 Mn. 

2.  Who are the major vendors in the liquid biopsy market?  

Ans. The major vendors in the liquid biopsy market are Natera, Inc.; Qiagen N.V.; Myriad Genetics, Inc.; Illumina, Inc.; Roche Group. 

3.  Which segments are covered under the liquid biopsy market segments analysis?  

Ans. The liquid biopsy market report offers in-depth insights into Product & Service, Application, Circulating Biomarker, End User, and Geography.